- Retreatment with trastuzumab in HER-2 positive metastatic breast cancer progressing after trastuzumab and lapatinib2012 | First Faculty of Medicine
- Trastuzumab and heart damage2012 | First Faculty of Medicine
- Pharmacological profile – trastuzumab emtansine2022 | Third Faculty of Medicine
- Trastuzumab-induced cardiotoxicity: a review2023 | Third Faculty of Medicine
- Trastuzumab deruxtecan: strong player in the field of metastatic HER2 positive breast cancer2022 | First Faculty of Medicine
- Trastuzumab deruxtecan in the treatment of patients with metastatic HER2‑low breast cancer2023 | First Faculty of Medicine
- What next for the failure of treatment with trastuzumab in HER2-dependent metastatic breast cancer2009 | First Faculty of Medicine
- Is there a qualitative interaction between adjuvant trastuzumab and size of the primary tumor in breast cancer?2008 | First Faculty of Medicine
- Trastuzumab in breast cancer treatment algorithm2010 | First Faculty of Medicine
- Trastuzumab emtansine in the treatment of residual HER2-positive breast cancer2019 | First Faculty of Medicine
- Trastuzumab deruxtecan as standard of care for second-line treatment of metastatic HER2-positive breast cancer2023 | First Faculty of Medicine
- Use of Trastuzumab for Neoadjuvant Therapy of HER2+ Breast Cancer - 5-Years of Experience in a Single Clinic2018 | First Faculty of Medicine
- Effect of neoadjuvant Herceptin (trastuzumab) in a patient with breast cancer with high growth activity2009 | First Faculty of Medicine
- Subcutaneous vs. intravenous application of trastuzumab in neoadjuvant setting in breast cancer HER2+ patient stage I-III, HannaH trial2012 | First Faculty of Medicine
- Trastuzumab deruxtekan2021 | First Faculty of Medicine
- Biological treatment with trastuzumab in the neoadjuvant therapy of breast cancer2009 | First Faculty of Medicine
- Report of University Hospital Hradec Králové to the clinical trial protocol No: BO27938Publication without faculty affiliation
- Is there a qualitative interaction between adjuvant trastuzumab and size of the primary tumor in breast cancer?2008 | Faculty of Medicine in Hradec Králové
- News in anti-HER2 targeted therapy in breast cancer +12013 | First Faculty of Medicine
- The current location of trastuzumab in the treatment of HER2 positive breast cancer2009 | First Faculty of Medicine
- Report of University Hospital Hradec Králové to the clinical trial protocol No: BO28407Publication without faculty affiliation
- The advantage of Herceptin SC and advantage of the originator2017 | Faculty of Medicine in Pilsen
- Research Report University Hospital clinical trial BO28407Publication without faculty affiliation
- Fixní kombinace pertuzumabu a trastuzumabu v subkutánní injekci2021 | First Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. Final report of University Hospital Hradec Kralove to the clinical trial protocol no. BO28407Publication without faculty affiliation
- Research Report University Hospital of the clinical trial BO27938Publication without faculty affiliation
- First-line trastuzumab (H), oral vinorelbine (NVBo) and capecitabine (X) combination therapy for HER2-positive metastatic breast cancer (MBC): efficacy and safety in a multinational phase 2 studyPublication without faculty affiliation
- Lapatinib and the treatment of metastatic breast cancer treated by trastuzumab2009 | First Faculty of Medicine
- Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era2011 | Third Faculty of Medicine